ClinicaliQ Trial Snapshot
- Dominantly Inherited Alzheimer Network (DIAN) — Recruiting • Neurology • NCT00869817.
- What is being tested: The study investigates biomarkers in individuals carrying dominant Alzheimer's disease mutations to predict disease onset and progression before symptom appearance.
- Patient eligibility overview: Participants include asymptomatic and symptomatic carriers of pathogenic mutations in APP, PSEN1, or PSEN2 genes, along with matched non-carrier controls for comparison.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.
Eligibility Snapshot
- : * Written informed consent obtained from participant and collateral source prior to any study-related procedures. * Aged 18 (inclusive) or older and the child of an affected individual (clinically or by testing) in a pedigree with a known mutation for ADAD. * Cognitively normal to very mild or mild cognitive impairment (CDR score range 0-1.0). Primary enrollment will focus on the recruitment of asymptomatic adult children who are more than 15 years younger than the estimated age of symptom onset. Enrollment of new participants with moderate cognitive impairment is allowed with the prior approval of the DIAN Coordinating Center. * Has two persons who are not their full-blooded siblings who can serve as collateral sources for the study. * Fluent in a language approved by the DIAN Coordinating Center at about the 6th grade level (international equivalent) or above.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.